Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ACT licenses technologies to develop HPV vaccine
August 2008
SHARING OPTIONS:

LOUISVILLE, Ky.Advanced Cancer Therapeutics (ACT), a private anti-cancer drug developer, has signed two collaborative agreements that will advance its novel vaccine program for human papillomavirus (HPV), a leading cause of cervical, anal and vaginal cancer. ACT's vaccine, to be produced in tobacco plants, targets the minor capsid, or L2, protein, an integral part of the papillomavirus capsid.

Under the first agreement, announced in July, the University of Louisville's James Graham Brown Cancer Center granted ACT exclusive worldwide development and commercialization rights to monovalent vaccines derived from L2. Under the second agreement, ACT has exclusive worldwide development and commercialization rights to Kentucky BioProcessing LLC (KBP)'s GENEWARE plant based gene expression system for development of an HPV vaccine. The GENEWARE system uses a specifically altered tobacco mosaic virus as a vehicle to carry a target protein. The natural growth of the plant produces large quantities of the protein. Financial terms of the agreements were not released.

"These agreements are central to the timely and efficient development of a novel vaccine and we look forward to continuing our collaborations as we work towards this common goal," says ACT president and CEO Randall B. Riggs. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.